Search Results for 'superficial femoral artery'
-
TORUS 2 Clinical Study Underway for Peripheral Artery Disease Treatment
PQ Bypass' technology has been evaluated in the TORUS 1 study in Europe and is currently under evaluation in the DETOUR 2 IDE in the U.S. and Europe.Business Wire 12.16.19
-
Cardiovascular
PQ Bypass Receives Unconditional IDE Approval From FDA to Start TORUS SFA Stent Graft Study
TORUS-2 marks second Investigational Device Exemption approved for company in less than two years.Business Wire 11.15.19
-
Cardiovascular | Surgical
Medtronic's IN.PACT Admiral Drug-Coated Balloon Approved to Treat Long SFA Lesions
New indication expands DCB treatment for patients with superficial femoral artery lesions up to 360mm.GlobeNewswire 04.24.18
-
Cardiovascular
Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device
The device received FDA 510(k) clearance earlier this year.Business Wire 06.27.17
-
Cardiovascular
PQ Bypass Announces CE Mark for DETOUR Percutaneous Bypass Technologies
Technologies expand treatment options for patients with extremely long superficial femoral artery blockages.Business Wire 03.24.17
-
PQ Bypass Announces Positive Results From DETOUR I Study
Trial evaluates percutaneous bypass treatment for PAD patients with complex superficial femoral artery occlusions.Business Wire 01.30.17
-
R&D & Design
FDA Approval for Gore’s Stent for Peripheral Artery Disease
Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies.W. L. Gore & Associates Inc. 08.02.16
-
Terumo Launches Self-Expanding Peripheral Stent to U.S. Market
Misago Rx received premarket approval in May.10.22.15
-
R&D & Design
Angioslide Makes European Launch of New Device for Treatment of Entire Superficial Femoral Artery
Proteus device combines balloon angioplasty and embolic capture of particles.09.08.11
